Market Outlook

By 2035, the U.S. Wearable Diabetes Care Devices Market is projected to reach approximately USD 38.92 billion, expanding at a CAGR of 12.05% during the forecast period 2026–2035. The market is estimated at USD 12.48 billion in 2025, following historical expansion from approximately USD 7.15 billion in 2021, USD 8.14 billion in 2022, USD 9.39 billion in 2023, and USD 10.88 billion in 2024. Values in this report are expressed in USD billions.

The U.S. wearable diabetes care devices industry is transitioning from a specialist diabetes technology category into a broader connected chronic-care infrastructure market. Continuous glucose monitors, wearable insulin pumps, automated insulin delivery systems, patch-based delivery technologies, long-duration glucose sensors, smartphone-connected diabetes devices, and emerging metabolic biosensors are increasingly becoming part of routine diabetes management rather than optional tools reserved for technologically advanced patients.

The underlying clinical opportunity is substantial. Current national estimates indicate that approximately 40.1 million people in the United States have diabetes, while more than 115 million U.S. adults have prediabetes. The economic burden is similarly significant. Diagnosed diabetes has been associated with more than USD 400 billion in annual direct and indirect economic costs, creating strong incentives for health plans, Medicare, employers, providers, and patients to adopt technologies capable of improving glucose control and reducing preventable complications.

Wearability is changing the economics of diabetes care because clinical management is moving away from isolated glucose measurements and episodic physician visits toward continuous data generation. A wearable glucose sensor can generate hundreds of glucose measurements every day, while connected insulin delivery systems can use those measurements to influence dosing decisions. This creates a fundamentally different care model from conventional finger-stick monitoring and manual insulin administration.

Continuous glucose monitoring represents the largest component of the market. However, the next phase of value creation is increasingly occurring at the intersection of glucose sensing, insulin delivery, algorithms, smartphone control, cloud-based analytics, and automated clinical decision support. The commercial emphasis is therefore moving from selling individual devices toward controlling connected diabetes ecosystems.

The U.S. market is particularly attractive because reimbursement, pharmacy-channel access, FDA interoperability pathways, advanced endocrinology infrastructure, consumer technology adoption, and strong manufacturer investment support faster penetration than in many international markets. Medicare coverage expansion has also widened the addressable CGM population beyond historically narrower intensive-insulin criteria, improving commercial access among older adults.

Over-the-counter glucose sensing represents another important expansion layer. The creation of FDA-cleared OTC CGM categories has opened glucose biosensing to adults who do not use insulin and, more recently, to additional age groups. This is expanding the wearable glucose market beyond conventional prescription-driven diabetes management into metabolic awareness, medication optimization, lifestyle management, and preventive health applications.

The historical market expanded rapidly between 2021 and 2025 as CGM penetration increased, pharmacy distribution broadened, automated insulin delivery became more clinically mainstream, sensor form factors became smaller, smartphone compatibility improved, and U.S. insurers expanded device coverage. The market also benefited from the transition from durable pump-centric business models toward recurring disposable sensors, patch pumps, transmitters, infusion supplies, and software-supported recurring revenue.

From 2026 through 2035, growth is expected to be increasingly driven by insulin-treated type 2 diabetes, non-insulin-treated populations suitable for CGM, automated insulin delivery expansion, OTC sensing, extended-wear sensors, lower device burden, interoperability, pharmacy access, and clinical integration of wearable-generated data.

The market model includes wearable CGM and biosensing systems, wearable insulin pumps and automated insulin delivery systems, patch-based insulin delivery technologies, connected wearable insulin-management devices, recurring wearable sensors and related components, and emerging diabetes-specific metabolic wearable technologies. Conventional standalone blood glucose meters that do not form part of a wearable ecosystem are excluded.

 

Introduction

According to the U.S. Wearable Diabetes Care Devices Market Report, diabetes management is entering a period in which continuous data, automation, connectivity, and patient self-management are becoming as strategically important as the therapeutic device itself.

Historically, diabetes technology required patients to perform multiple manual tasks. Glucose measurements were intermittent, insulin dosing required calculation, treatment data were fragmented, and physicians generally evaluated glycemic performance retrospectively during periodic consultations. Wearable diabetes technologies are replacing this model with continuous monitoring, predictive alerts, remote data sharing, automated insulin adjustment, and longitudinal clinical visibility.

Continuous glucose monitoring has become the foundational wearable technology in this transformation. Modern CGM platforms provide real-time glucose values, directional trends, hypoglycemia and hyperglycemia alerts, historical patterns, and increasingly seamless sharing with caregivers and healthcare professionals. The clinical value proposition is no longer limited to eliminating finger sticks. CGM data can support decisions around medication adjustment, insulin dosing, nutrition, physical activity, sleep, and hypoglycemia prevention.

The scale of commercial adoption can be seen in manufacturer performance. Leading CGM franchises now generate several billion dollars in annual global revenue, while major wearable insulin-delivery companies are recording double-digit growth. Abbott reported approximately USD 6.8 billion in Diabetes Care revenue in 2024, largely associated with its FreeStyle Libre franchise, while Dexcom surpassed USD 4 billion in global annual revenue during the same period and continued expanding thereafter. Insulet generated approximately USD 1.92 billion from the U.S. market alone in 2025, demonstrating the commercial scale already achieved by tubeless insulin delivery.

Wearable diabetes technology is also moving deeper into type 2 diabetes. This is strategically important because type 2 diabetes represents the overwhelming majority of diagnosed U.S. diabetes cases. Historically, premium wearable technologies were concentrated among people with type 1 diabetes or patients requiring intensive insulin therapy. Regulatory expansions, broader reimbursement, improved ease of use, lower sensor burden, and stronger evidence are progressively widening that eligible population.

FDA expansion of automated insulin delivery into insulin-requiring type 2 diabetes represents an important inflection point. Omnipod 5 became the first automated insulin dosing technology cleared for adults with type 2 diabetes in 2024. Medtronic subsequently received U.S. approval for MiniMed 780G use among insulin-requiring adults with type 2 diabetes. These developments indicate that AID is evolving from a predominantly type 1 diabetes technology into a larger insulin-management platform.

The procurement environment is also changing. Unlike large hospital capital equipment markets, wearable diabetes devices are substantially influenced by outpatient endocrinology, primary care, pharmacies, durable medical equipment suppliers, pharmacy benefit managers, Medicare, Medicaid, commercial insurers, and consumer preference. Market access therefore depends on reimbursement architecture and formulary positioning as much as on physician preference.

Manufacturers increasingly compete on sensor wear duration, accuracy, warm-up time, application simplicity, smartphone integration, pump compatibility, alert burden, adhesive performance, automated dosing capability, data-sharing functionality, cost, reimbursement access, and patient retention.

For investors, manufacturers, healthcare systems, payers, distributors, and digital health companies, the strategic question is not whether wearable diabetes technology will continue growing. The more important questions are which patient populations will convert next, which platforms will control interoperability, how recurring sensor economics will evolve, whether pharmacy distribution will displace traditional DME pathways, and how automation will alter competitive share between established diabetes technology manufacturers and new entrants.

 

Key Market Drivers: What’s Fueling the U.S. Wearable Diabetes Care Devices Market Boom?

The most fundamental market driver is the scale of U.S. diabetes and prediabetes. Approximately 40 million Americans are estimated to have diabetes, while the prediabetes population exceeds 115 million adults. Diabetes prevalence rises substantially with age, creating strong overlap between disease burden and the large Medicare population.

This clinical burden creates recurring demand rather than one-time procedural demand. Diabetes requires daily management, and wearable devices are well suited to a disease in which therapeutic decisions depend on changing glucose levels throughout the day. Unlike conventional episodic diagnostic devices, CGMs and wearable insulin-delivery products generate recurring replacement revenue from sensors, pods, infusion sets, cartridges, adhesives, and related supplies.

A second major driver is expanding CGM eligibility. The addressable U.S. market has progressively moved beyond people with type 1 diabetes using intensive insulin regimens. Medicare coverage now includes qualifying insulin-treated beneficiaries and certain individuals with problematic hypoglycemia. Commercial payers have also expanded access, although coverage policies and out-of-pocket exposure continue to vary.

The opening of OTC CGM represents another structural demand catalyst. FDA authorization of prescription-free glucose biosensors lowers the traditional physician-access barrier and creates a potential route to millions of consumers who do not use insulin. These products could expand glucose sensing into people with type 2 diabetes managed through oral therapies, individuals with prediabetes, and health-conscious consumers interested in understanding metabolic responses to food and exercise.

A third driver is automated insulin delivery. AID systems connect CGM measurements with algorithm-driven insulin pumps and automatically adjust insulin delivery based on glucose trends. The economic value of these platforms comes from their potential to improve time in range while reducing patient decision burden. As interoperability improves, device competition is shifting from individual pumps toward combinations of sensors, pumps, dosing algorithms, mobile applications, and cloud services.

A fourth driver is the transition of diabetes care toward home-based chronic disease management. Diabetes generates substantial outpatient utilization and requires frequent decisions that cannot realistically occur inside hospitals. Wearable devices move disease monitoring directly into the patient’s daily environment and allow physicians to evaluate longitudinal information remotely.

Remote monitoring is especially valuable for endocrinology practices managing large patient populations. Instead of relying primarily on HbA1c values collected during periodic appointments, clinicians can review time in range, glucose variability, overnight patterns, hypoglycemic exposure, sensor utilization, and therapy-response data.

A fifth driver is pharmacy-channel expansion. Moving wearable diabetes technology into pharmacy benefits can shorten onboarding, reduce dependence on specialized DME workflows, improve patient familiarity, and expand access through existing retail and mail-order channels. This has significant strategic implications for manufacturers because formulary positioning, rebate structures, PBM contracts, and retail availability increasingly influence market share.

A sixth driver is improving device usability. Sensor size has declined substantially, application mechanisms have become simpler, calibration requirements have been reduced or eliminated for many platforms, smartphone compatibility has improved, and wearable pumps are becoming smaller and easier to conceal. Improved usability directly affects persistence because diabetes devices must be worn continuously over long periods.

A seventh driver is the economic burden of poorly controlled diabetes. Total U.S. diabetes-related economic costs have been estimated at approximately USD 412.9 billion annually, including more than USD 300 billion in direct medical expenditure. Devices capable of reducing severe hypoglycemia, hyperglycemia, emergency utilization, and long-term complications therefore have potential value extending beyond the immediate device purchase.

Finally, consumer expectations are changing. Patients increasingly expect diabetes devices to function with the simplicity of consumer electronics. Smartphone control, discreet wear, real-time sharing, automatic software updates, simplified onboarding, and low cognitive burden are becoming competitive requirements rather than premium differentiators.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in wearable diabetes care is increasingly centered on reducing the amount of human intervention required to maintain safe glucose control.

The first major innovation frontier is longer sensor life. Conventional wearable CGMs require periodic sensor replacement, creating cost, inconvenience, adhesive burden, and interruption risk. Manufacturers are therefore extending wear duration while improving accuracy and reliability. Fifteen-day sensors and implantable sensors capable of operating for up to a year demonstrate the direction of travel.

Long-duration sensing could materially alter market economics. A patient changing a sensor every ten to fifteen days interacts with the product differently from a patient using an implanted sensor for many months. Short-duration disposable CGM favors high recurring sensor volumes, while implantable sensing shifts more economic value toward insertion procedures, long-duration reliability, transmitter economics, and patient retention.

The second innovation frontier is automated insulin delivery. Modern systems increasingly automate basal insulin adjustment and correction dosing using continuously generated CGM data. Competition is evolving around algorithm performance, glucose targets, meal handling, setup simplicity, interoperability, and how much decision burden remains with the patient.

The expansion of AID into type 2 diabetes could be transformative. Type 2 diabetes represents a significantly larger potential population than type 1 diabetes. Even modest penetration among insulin-intensive type 2 patients can create a substantial new revenue pool for pump, CGM, consumable, and software manufacturers.

The third innovation frontier is sensor-pump interoperability. Historically, many diabetes ecosystems were vertically integrated and limited to particular sensor and pump combinations. The market is gradually becoming more open. Tandem, Beta Bionics, Insulet, Medtronic, Abbott, Dexcom, Senseonics, and newer insulin-delivery developers are increasingly participating in multi-device integration strategies.

Interoperability changes procurement behavior because physicians and patients can potentially select the preferred sensor and insulin-delivery platform separately. It also creates strategic pressure on manufacturers to secure integration agreements because an isolated device may become commercially disadvantaged if it cannot participate in leading AID ecosystems.

The fourth frontier is OTC metabolic sensing. Prescription-free glucose biosensors represent one of the most commercially disruptive developments in the category. This model changes the customer acquisition pathway from physician prescription toward direct-to-consumer education, online ordering, retail purchasing, employer wellness, and preventive-health engagement.

The fifth frontier is implantable CGM. Eversense 365 demonstrates the potential for continuous glucose monitoring for up to one year using an implanted sensor. The technology addresses sensor-replacement burden differently from conventional disposable CGMs and provides a distinct competitive proposition for users seeking long-duration monitoring.

The sixth innovation frontier is miniaturization. Smaller pumps, integrated insertion mechanisms, reduced transmitter profiles, discreet patch pumps, and wearable form factors are improving device acceptance. Tandem Mobi, compact patch systems, tubeless pumps, and increasingly small CGM sensors reflect the importance of minimizing physical intrusion into everyday life.

AI and advanced analytics represent the seventh frontier. Diabetes data volumes are increasing dramatically as CGM generates continuous readings. The competitive opportunity is therefore moving toward interpreting data rather than simply collecting it. Future platforms are expected to prioritize predictive hypoglycemia, automated treatment adjustment, pattern recognition, personalized glucose targets, therapy optimization, and clinician workflow prioritization.

Cybersecurity, software reliability, and human-factors engineering are simultaneously becoming more important. A connected diabetes device is both a medical device and a software system. Software errors, failed alerts, connectivity issues, incorrect dosing commands, or inaccurate sensor readings can create significant patient-safety consequences. Regulatory expectations around software validation and post-market surveillance are therefore likely to increase as automation becomes deeper.

 

Segmentation Insights

The U.S. Wearable Diabetes Care Devices Market is segmented on the basis of product type, diabetes type, end user, technology and connectivity, and region.

 

By Product Type

Continuous Glucose Monitoring Systems

Continuous glucose monitoring systems represent the largest product segment, accounting for an estimated USD 7.25 billion of the U.S. market in 2025. The segment includes disposable wearable sensors, transmitters where required, receivers, integrated CGM systems, implantable glucose sensors, and associated wearable components.

CGM is expected to remain the principal revenue pool through 2035 because it serves both insulin-treated and increasingly non-insulin-treated populations. Adoption benefits from strong clinical awareness, recurring sensor replacement, Medicare and commercial reimbursement, pharmacy access, integration with insulin delivery, and consumer acceptance.

The segment is projected to reach approximately USD 21.40 billion by 2035, reflecting continued expansion into type 2 diabetes and OTC glucose sensing. Abbott and Dexcom currently define much of the competitive intensity in disposable CGM, while Senseonics provides a differentiated long-duration implantable approach.

Wearable Insulin Pumps and Automated Insulin Delivery Systems

Wearable pumps and AID systems generated an estimated USD 4.00 billion in 2025 and represent one of the highest-value diabetes technology segments.

Products include tubed pumps, compact pumps, tubeless patch pumps, algorithm-controlled insulin delivery systems, controllers, related consumables, and integrated AID configurations. Insulet, Medtronic, Tandem Diabetes Care, Beta Bionics, and emerging developers compete across different form factors and automation philosophies.

This segment is projected to reach approximately USD 13.20 billion by 2035, driven by higher pump penetration, type 2 diabetes indications, improved usability, algorithmic automation, interoperability, and increased CGM adoption.

Patch-Based Insulin Delivery Devices

Patch-based insulin delivery represents an estimated USD 0.85 billion market in 2025 when products outside the major integrated pump category and associated simplified wearable-delivery approaches are considered.

Patch technologies appeal to patients who want alternatives to multiple daily injections but may not want conventional pump tubing or complex pump interfaces. Future growth is likely to be strongest in type 2 diabetes, where simplicity and physician onboarding can matter more than advanced pump customization.

The segment is projected to approach USD 2.90 billion by 2035, corresponding to an approximate 13% CAGR.

Connected Wearable Insulin-Management Accessories

Connected wearable insulin-management devices and accessories represent a smaller but strategically important category, estimated at approximately USD 0.25 billion in 2025.

Products include connected dosing aids, wearable controllers, smart injection-related technologies, and accessories that allow insulin administration data to become part of a broader glucose-management ecosystem. Their value lies in connecting therapies that historically generated little digital information.

The segment could approach USD 0.65 billion by 2035 as connected multiple-daily-injection management becomes more integrated with CGM.

Emerging Wearable Metabolic and Multianalyte Biosensors

Emerging glucose, ketone, metabolic, and multianalyte wearables generated a relatively small estimated USD 0.13 billion in 2025, but represent the fastest technology opportunity from a low base.

The category could reach approximately USD 0.77 billion by 2035, corresponding to a CAGR approaching 20%. Commercial success will depend heavily on analytical accuracy, clinical relevance, reimbursement, FDA positioning, consumer retention, and whether additional biomarkers generate actionable information rather than simply additional data.

 

By Diabetes Type

Type 1 Diabetes

Type 1 diabetes remains the most technology-intensive patient segment. Continuous insulin requirements, elevated hypoglycemia risk, frequent glucose fluctuations, and the need for precise dose adjustment make CGM and AID particularly valuable.

Wearable penetration is already comparatively high among technologically engaged type 1 patients. Future revenue growth will therefore be driven less by establishing the clinical relevance of wearable technology and more by upgrading patients to better sensors, higher automation, smaller pumps, improved algorithms, interoperable platforms, and longer-duration devices.

Pediatric adoption is particularly important because children and caregivers benefit from remote glucose sharing, predictive alerts, and automated insulin adjustment.

Insulin-Treated Type 2 Diabetes

Insulin-treated type 2 diabetes represents one of the most important incremental growth pools through 2035.

The segment combines a large patient population with historically lower penetration of advanced diabetes technology. Expansion of CGM coverage and AID indications is progressively reducing this gap. FDA authorization of automated insulin delivery for adults with type 2 diabetes confirms that the clinical boundary between type 1 and type 2 diabetes technology is becoming less rigid.

Manufacturers that simplify onboarding will have an advantage because many type 2 patients are managed outside specialist endocrinology settings.

Non-Insulin-Treated Type 2 Diabetes

Non-insulin-treated type 2 diabetes is expected to become a major CGM growth frontier even though insulin-delivery devices have limited relevance to this population.

The commercial argument centers on medication response, nutrition, exercise, glucose variability, and identification of hyperglycemic patterns. OTC CGM increases the importance of this category because users may gain access without a traditional prescription pathway.

Long-term adoption will depend on demonstrating that continuous sensing produces durable clinical or behavioral value rather than short-term novelty.

Prediabetes and Metabolic-Risk Users

The enormous U.S. prediabetes population creates a potentially large but less clinically established market for wearable glucose sensing.

The commercial opportunity is attractive because more than 100 million adults may have prediabetes. However, the market should not be equated with the established prescription diabetes-device population. Sustained growth will depend on consumer willingness to pay, employer wellness models, evidence that wearables meaningfully change behavior, and appropriate interpretation of glucose data.

Gestational and Other Diabetes Populations

Pregnancy-related diabetes and other specialized diabetes populations represent smaller segments but can benefit significantly from frequent glucose monitoring because glycemic targets may be particularly important during pregnancy or complex treatment periods.

Technology adoption in these populations depends heavily on clinician oversight, device labeling, reimbursement, treatment intensity, and specialist involvement.

 

By End User

Home and Patient Self-Management

Home and individual patient use represents the dominant end-user segment because wearable diabetes devices are designed for continuous use outside institutional settings.

This differentiates the market from hospital-centric medical device categories. The patient is simultaneously the wearer, data generator, daily operator, and frequently an important purchase decision participant. Device comfort, training, adhesive performance, smartphone compatibility, alert burden, customer support, and replacement logistics therefore have direct commercial implications.

Retention is economically critical. A patient who consistently uses CGM generates recurring sensor demand, while a patient who discontinues within months can materially reduce lifetime value.

Endocrinology and Diabetes Specialty Practices

Endocrinologists, diabetes educators, and specialty clinics remain the most influential professional adopters.

These providers often determine which patients move from conventional monitoring to CGM, from injections to pumps, or from standalone devices to automated insulin delivery. They are also responsible for reviewing large volumes of patient-generated data.

Platforms that simplify clinical reports, reduce data-download burden, standardize time-in-range analysis, and integrate with electronic health records can therefore influence prescribing behavior beyond basic device performance.

Primary Care Practices

Primary care is becoming increasingly important as wearable technology expands into type 2 diabetes.

The majority of people with type 2 diabetes are not managed exclusively by endocrinologists. Sustainable mass-market CGM adoption therefore requires workflows that primary care physicians, nurse practitioners, pharmacists, and care-management teams can use without specialized device expertise.

Simplified prescribing, pharmacy fulfillment, automated interpretation, and standardized clinical dashboards will be especially important.

Hospitals and Integrated Health Systems

Hospitals are not the primary usage environment for most wearable diabetes devices, but health systems influence adoption through discharge planning, endocrinology programs, formularies, employee health plans, specialty pharmacies, inpatient-to-outpatient transitions, and population-health programs.

Integrated delivery networks may increasingly evaluate diabetes wearables through total-cost-of-care frameworks, particularly when they operate value-based contracts.

Telehealth, Remote Monitoring and Digital Diabetes Providers

Telehealth and virtual diabetes programs represent an emerging end-user ecosystem.

Wearable glucose data make remote management clinically richer because providers can evaluate glucose patterns between virtual appointments. Digital platforms can combine sensor data with medication management, nutrition coaching, behavioral interventions, and automated alerts.

This segment will become increasingly important if payers move from reimbursing individual devices toward contracts based on measurable outcomes.

 

By Technology and Connectivity

Standalone Continuous Sensing

Standalone CGM remains the largest technology architecture. The device measures glucose continuously and presents information through a receiver or smartphone without automatically controlling insulin delivery.

Its addressable population is broad because users do not need to be pump candidates. This architecture is particularly important in type 2 diabetes and OTC markets.

CGM-Integrated Automated Insulin Delivery

CGM-integrated AID represents the highest-value technology architecture.

These systems connect continuous glucose information to automated dosing algorithms and insulin pumps. Their strategic importance derives from combining multiple revenue layers: sensors, pumps, recurring disposable components, software, algorithms, and support services.

The category is expected to gain share as FDA indications broaden and interoperability improves.

Smartphone-First Connected Devices

Smartphones increasingly function as the primary interface for diabetes technology. Glucose readings, alerts, pump controls, caregiver sharing, trend visualization, and device settings can increasingly be managed through mobile applications.

Smartphone-first design reduces the need for dedicated receivers, but it also introduces software-compatibility, operating-system, cybersecurity, battery, usability, and regulatory considerations.

Cloud-Connected and AI-Assisted Platforms

Cloud platforms increasingly aggregate longitudinal glucose and insulin data for clinicians, patients, and caregivers.

Over time, AI-assisted analytics are expected to prioritize patients who require intervention, identify glucose patterns, predict risk, support treatment adjustments, and reduce manual review burden.

The commercial differentiation will increasingly depend on how effectively manufacturers convert raw sensor data into actionable decisions.

Long-Duration and Implantable Sensors

Long-duration implantable sensing represents a differentiated technology pathway.

Eversense 365, designed for up to one year of glucose sensing, substantially changes the replacement cycle relative to short-duration disposable CGMs. The model may appeal to users seeking fewer sensor changes, although insertion procedures and provider participation create different workflow requirements.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. Wearable Diabetes Care Devices Market is geographically segmented into the South, West, Northeast, and Midwest. Regional performance is influenced by population size, diabetes prevalence, Medicare concentration, commercial insurance coverage, specialist access, pharmacy infrastructure, rural healthcare availability, health-system concentration, consumer technology adoption, and payer reimbursement policies.

The South represents the largest regional market in 2025, while the West is expected to record the fastest CAGR through 2035. The Northeast remains a high-value adoption market because of strong academic medicine and insurer penetration, while the Midwest provides substantial recurring demand through large integrated health systems and established diabetes programs.

South

The South represents an estimated USD 4.62 billion market in 2025, equivalent to approximately 37% of national wearable diabetes device revenue. The region is projected to reach approximately USD 14.21 billion by 2035, reflecting an estimated CAGR of approximately 11.9%.

Its leadership is supported by population scale, elevated diabetes prevalence across several Southeastern states, large Medicare populations, strong metropolitan growth, and substantial unmet need in rural communities. Recent U.S. public-health analysis continues to show that states with comparatively high diabetes burden are disproportionately concentrated in the Southeast.

Texas and Florida are the most commercially important Southern state markets.

Texas combines approximately 30 million residents with major healthcare hubs in Houston, Dallas-Fort Worth, Austin, and San Antonio. The state supports large endocrinology practices, health systems, employer-sponsored insurance markets, specialty pharmacies, and growing digital-health adoption. Its combination of metropolitan technology adoption and rural access challenges makes it relevant for both premium AID systems and remotely managed CGM.

Florida is particularly important because of its large older population. Medicare coverage is therefore a powerful determinant of CGM penetration. The state’s aging demographics also increase the importance of hypoglycemia management, simplified device interfaces, caregiver sharing, and pharmacy fulfillment.

North Carolina, Georgia, Virginia, and Tennessee represent increasingly attractive wearable diabetes markets due to population growth, sophisticated health systems, expanding specialty-care capacity, and large suburban populations.

North Carolina is strategically notable because public-health research has identified substantial rural diabetes burden in portions of the state. This creates a strong use case for remote monitoring and technology-enabled diabetes management where access to endocrinology is limited.

Mississippi, Alabama, Louisiana, Kentucky, Arkansas, Oklahoma, and West Virginia face particularly significant chronic metabolic disease burdens. These states create substantial medical need but present different commercial economics from wealthier metropolitan markets. Manufacturer success depends heavily on Medicare, Medicaid, pharmacy access, affordability, diabetes education, and low-complexity onboarding.

The region’s largest opportunity is therefore not simply premium technology adoption. It is expanding advanced wearable diabetes management into populations that historically had inadequate access to specialty diabetes technology.

West

The West accounted for an estimated USD 2.75 billion in 2025 and is forecast to reach approximately USD 9.46 billion by 2035, corresponding to an estimated 13.15% CAGR, the fastest among the four regions.

California is the dominant Western market. Its importance reflects population scale, large commercially insured populations, major academic healthcare systems, strong technology adoption, extensive digital-health infrastructure, and proximity to many diabetes technology companies.

California is particularly important for CGM, smartphone-centric diabetes management, digital therapeutics, AI-supported analytics, clinical trials, and early consumer adoption of metabolic wearables. Health systems and endocrinology groups in major metropolitan areas are frequently early adopters of new digital health workflows.

Arizona and Nevada offer strong growth potential because of population growth and aging demographics. Arizona’s expanding retirement population increases Medicare-related demand, while Phoenix and other metropolitan areas provide increasing access to endocrinology and advanced diabetes care.

Washington and Oregon have strong connected-health environments and sophisticated integrated delivery networks. Rural diabetes access remains an issue outside major metropolitan corridors, strengthening the value proposition for remote monitoring.

Colorado and Utah are attractive markets because of younger technology-oriented populations, advanced integrated health systems, and relatively high digital engagement. These states may be particularly receptive to smartphone-first devices, metabolic sensing, and virtual diabetes-management programs.

New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii represent smaller revenue pools but highlight the geographic-access advantages of remote glucose monitoring. In geographically dispersed populations, technologies that allow clinicians to evaluate glucose remotely can reduce the dependency on frequent physical specialist visits.

The West is expected to gain national share through 2035 because it combines clinical adoption with digital technology development. The region is likely to be an important testing ground for OTC glucose sensing, AI analytics, consumer metabolic wearables, and new virtual-care business models.

Northeast

The Northeast represented an estimated USD 2.62 billion in 2025 and is projected to reach approximately USD 7.79 billion by 2035, reflecting an estimated CAGR of approximately 11.5%.

New York represents the region’s largest state opportunity due to its population, concentrated healthcare infrastructure, extensive Medicaid and commercial insurance populations, major academic centers, and dense endocrinology networks.

New York City creates a particularly large opportunity for pharmacy-distributed CGM and diabetes technologies because patients can access large health systems, retail pharmacies, specialists, and digital-health services within a concentrated geography. Upstate areas create different challenges related to specialist access and rural care.

Massachusetts has a smaller population but substantial strategic influence. Boston’s academic medical centers, clinical research infrastructure, biotechnology ecosystem, and sophisticated payer environment make the state an important early-adoption and evidence-generation market.

Pennsylvania and New Jersey provide large recurring patient populations and extensive health-system networks. Philadelphia, Pittsburgh, northern New Jersey, and suburban markets provide attractive concentrations of endocrinology and diabetes-management infrastructure.

Connecticut, Rhode Island, New Hampshire, Vermont, Maine, and Delaware are smaller markets but often have comparatively strong healthcare access and insurance coverage. Northern rural areas also create opportunities for remote monitoring and tele-endocrinology.

The Northeast is expected to remain a premium adoption region rather than the fastest volume-growth region. Manufacturers seeking adoption of advanced AID systems, long-duration sensors, and clinically differentiated platforms can benefit from the region’s specialist density and evidence-oriented provider environment.

Midwest

The Midwest represented approximately USD 2.49 billion in 2025 and is projected to reach around USD 7.46 billion by 2035, reflecting an estimated CAGR of approximately 11.6%.

Illinois is the largest Midwestern state market, with Chicago providing a major concentration of academic medical centers, health systems, endocrinologists, pharmacies, employers, and commercially insured patients.

Ohio and Michigan represent substantial diabetes markets because of large populations, established integrated delivery networks, and meaningful chronic disease burden. Health systems in Cleveland, Columbus, Cincinnati, Detroit, and Ann Arbor are influential in diabetes technology adoption and clinical education.

Minnesota has strategic importance beyond population size because of its long-standing medtech ecosystem and integrated healthcare infrastructure. The state is highly relevant for medical-device innovation, payer-provider collaboration, and technology-driven chronic disease management.

Wisconsin, Indiana, and Missouri provide stable recurring demand. Iowa, Kansas, Nebraska, North Dakota, and South Dakota have smaller populations but substantial rural geographies, creating potential for connected CGM and virtual diabetes care.

A recent U.S. analysis found diabetes prevalence materially higher in rural than urban populations nationally before demographic adjustment, illustrating why geographic access remains commercially important across portions of the Midwest.

The Midwest is unlikely to outpace the West in percentage growth, but it represents a durable and strategically important market because of established diabetes programs, strong regional referral systems, large employer populations, and health-system purchasing influence.

 

Key Market Players

The competitive landscape of the U.S. Wearable Diabetes Care Devices Market is concentrated around a limited number of scaled CGM and insulin-delivery leaders, but the broader ecosystem includes specialized pump developers, long-duration sensor companies, diabetes software businesses, device distributors, connected-care providers, and emerging biosensor developers.

Relevant companies and competitive participants include Abbott Laboratories, Dexcom, Medtronic, Insulet Corporation, Tandem Diabetes Care, Senseonics Holdings, Beta Bionics, Sequel Med Tech, embecta, CeQur, Modular Medical, Ascensia Diabetes Care, Roche Diabetes Care, LifeScan, AgaMatrix, DarioHealth, Glooko, Teladoc Health/Livongo, Ypsomed, EOFlow, Nemaura Medical, i-SENS, and Sinocare.

Not all participants have equivalent U.S. commercial scale or regulatory positioning. Abbott and Dexcom dominate the disposable CGM conversation, while Insulet, Medtronic, and Tandem hold major positions in wearable insulin delivery. Beta Bionics is creating additional competitive pressure through autonomous dosing, while Senseonics differentiates around long-duration implantable CGM.

Insulet’s growth demonstrates the increasing attractiveness of tubeless insulin delivery. The company’s U.S. Omnipod revenue reached approximately USD 1.92 billion in 2025, increasing more than 27% year over year, while its global active user base surpassed approximately 600,000.

Tandem Diabetes Care surpassed approximately USD 1 billion in worldwide sales during 2025, supported by an installed base approaching 500,000 users globally. Its strategy increasingly centers on a portfolio that includes t X2, Tandem Mobi, sensor integration, and automated insulin delivery.

Dexcom generated approximately USD 4.65 billion in organic global revenue during 2025, demonstrating the recurring-revenue scale attainable in CGM. Abbott’s diabetes franchise remains similarly influential, supported by FreeStyle Libre and expansion into consumer biowearables.

Competition through 2035 will increasingly be determined by ecosystem breadth rather than hardware specifications alone. CGM companies need pump integrations; pump companies need competitive sensors; software platforms need access to high-quality device data; and payers need evidence that technology improves measurable outcomes.

The strongest competitors will therefore be companies that can combine sensor performance, dosing automation, patient experience, payer access, manufacturing scale, clinical evidence, pharmacy distribution, cybersecurity, interoperability, and data infrastructure.

 

Recent Developments

Recent developments demonstrate how rapidly the U.S. wearable diabetes technology market is broadening its addressable population.

One of the most consequential developments was the creation of an OTC CGM pathway. Dexcom’s Stelo became the first FDA-cleared over-the-counter continuous glucose monitor in 2024 for adults who do not use insulin. Abbott subsequently received FDA clearance for OTC glucose-monitoring technologies including Libre Rio. These products are expanding the category beyond conventional prescription diabetes management.

In June 2026, FDA clearance further expanded OTC CGM availability by allowing the Stelo platform to serve people as young as two years old who do not use insulin. This illustrates continued regulatory movement toward broader glucose-sensing access.

Automated insulin delivery has simultaneously expanded into type 2 diabetes. In August 2024, the FDA expanded Insulet’s SmartAdjust technology for adults with type 2 diabetes, creating the first automated insulin dosing option for this population.

In 2025, Medtronic received U.S. authorization expanding the MiniMed 780G system to adults with insulin-requiring type 2 diabetes. The system’s interoperability roadmap also advanced through integration with Abbott-developed sensing technology, underscoring the broader movement toward cross-manufacturer diabetes ecosystems.

Long-duration CGM has also advanced. FDA clearance of Eversense 365 created a wearable/implantable glucose-monitoring system capable of continually measuring glucose for up to one year. Senseonics subsequently reported accelerating U.S. revenue as the product entered commercialization.

Commercial momentum remains strong. Insulet reported more than 30% worldwide revenue growth in 2025 and approximately 27% U.S. Omnipod growth. Tandem exceeded USD 1 billion in annual global revenue, while Dexcom continued reporting double-digit revenue expansion.

The competitive environment is also becoming more safety-sensitive. Recent corrective actions and recalls involving connected CGM software and insulin-delivery components illustrate the importance of software validation, alert reliability, manufacturing quality, and post-market surveillance. As devices become more automated, quality failures have potentially greater clinical consequences because patients increasingly depend on continuous device operation.

This creates an important strategic implication: future market leadership will require not only faster innovation but also extremely high reliability across hardware, sensors, algorithms, applications, wireless connectivity, cloud infrastructure, and cybersecurity.

 

Conclusion

The U.S. Wearable Diabetes Care Devices Market Size & Share is projected to expand from approximately USD 12.48 billion in 2025 to USD 38.92 billion by 2035, representing a 12.05% CAGR during 2026–2035.

The market is being reshaped by one of the most important transitions in chronic disease management: the movement from periodic measurement and manual intervention toward continuous sensing and increasingly automated therapy.

CGM will remain the largest revenue category, expanding from an estimated USD 7.25 billion in 2025 to approximately USD 21.40 billion by 2035. However, the fastest strategic value creation will increasingly occur around CGM-integrated automated insulin delivery, type 2 diabetes technology penetration, OTC sensing, extended sensor life, interoperable platforms, artificial intelligence, and simplified wearable insulin delivery.

The addressable patient population is expanding simultaneously in multiple directions. Type 1 diabetes remains the most technology-intensive segment, but insulin-treated type 2 diabetes is becoming increasingly important for both CGM and AID. Non-insulin-treated type 2 diabetes represents a large sensing opportunity, while the enormous prediabetes population creates a longer-term consumer and preventive-health market.

The commercial model is also changing. Diabetes wearable companies increasingly operate recurring-revenue businesses based on replacement sensors, pods, infusion supplies, subscriptions, and connected services. This produces attractive lifetime economics when patient retention is high but places considerable pressure on manufacturers to maintain device comfort, reliability, reimbursement, customer support, and continuous product innovation.

Regionally, the South is expected to remain the largest U.S. market because of population scale and diabetes burden. The West is forecast to grow fastest due to technology adoption, digital health integration, consumer acceptance, and strong innovation ecosystems. The Northeast will remain an important premium clinical adoption market, while the Midwest will provide stable recurring demand and substantial opportunities for connected rural diabetes management.

The competitive landscape will increasingly revolve around ecosystems rather than individual products. Abbott, Dexcom, Medtronic, Insulet, Tandem Diabetes Care, Senseonics, Beta Bionics, and emerging competitors are positioning themselves around combinations of sensing, automated insulin delivery, algorithms, smartphone interfaces, interoperability, and longitudinal patient data.

For clients evaluating this market, the most important commercial question is no longer simply how many people use a CGM or insulin pump. The more strategic questions are how rapidly wearable technology penetrates type 2 diabetes, whether OTC glucose sensing creates a durable new market, which manufacturers control the preferred AID combinations, how pharmacy and reimbursement channels evolve, and whether continuous data can create measurable reductions in total diabetes-related healthcare utilization.

The winners through 2035 are likely to be companies that reduce the physical and cognitive burden of diabetes while simultaneously improving measurable outcomes. Smaller sensors, longer wear periods, simpler insulin delivery, interoperable platforms, automation, strong reimbursement access, and reliable clinical data will define the competitive hierarchy.

The U.S. wearable diabetes care devices industry is therefore evolving from a device market into a continuously connected disease-management infrastructure. Companies capable of integrating sensing, therapy, software, evidence, reimbursement, and patient experience will control a disproportionate share of the next decade’s value creation.

 

TABLE OF CONTENT

1. U.S. Wearable Diabetes Care Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.2.1. Wearable Continuous Glucose Monitoring Devices
1.2.2. Wearable Insulin Delivery and Pump Systems
1.2.3. Automated Insulin Delivery Systems
1.2.4. Patch-Based Diabetes Care Devices
1.2.5. Connected Diabetes Monitoring and Management Devices
1.2.6. Emerging Wearable Metabolic Biosensors
1.2.7. Market Inclusion and Exclusion Criteria
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Bottom-Up and Top-Down Market Sizing
1.3.6. Patient Population and Device Penetration Modeling
1.3.7. Installed-Base and Recurring Consumables Modeling
1.3.8. ASP, Sensor Replacement and Utilization Modeling
1.3.9. Analytical Frameworks & Forecasting Models
1.3.10. Data Triangulation, Validation and Final Report Publishing
1.4. Key Assumptions
1.4.1. Historical Period, 2021–2024
1.4.2. Base Year, 2025
1.4.3. Forecast Period, 2026–2035
1.4.4. Revenue Measurement in US$ Billion
1.4.5. Device Replacement and Recurring Revenue Assumptions
1.4.6. Reimbursement and Patient Access Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Continuous Glucose Monitoring Manufacturers
1.6.2. Insulin Pump and Automated Insulin Delivery Manufacturers
1.6.3. Sensor, Semiconductor and Component Suppliers
1.6.4. Contract Manufacturing Organizations
1.6.5. Endocrinologists and Diabetes Specialty Practices
1.6.6. Primary Care Providers
1.6.7. Hospitals and Integrated Health Systems
1.6.8. Retail and Specialty Pharmacies
1.6.9. Durable Medical Equipment Suppliers
1.6.10. Pharmacy Benefit Managers
1.6.11. Commercial Health Plans
1.6.12. Medicare and Medicaid Programs
1.6.13. Telehealth and Digital Diabetes Care Providers
1.6.14. Patients and Caregivers
1.6.15. FDA, CMS and Other Regulatory Stakeholders

What this section provides: This section establishes the definition, boundaries, methodology, assumptions, revenue framework, device inclusion criteria, and stakeholder ecosystem used to measure and validate the U.S. wearable diabetes care devices market.

2. U.S. Wearable Diabetes Care Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size & CAGR Snapshot
2.8. Leading and Fastest-Growing Segments
2.9. CGM Adoption and Penetration Snapshot
2.10. Automated Insulin Delivery Adoption Snapshot
2.11. Prescription vs. OTC Wearable Glucose Monitoring Opportunity
2.12. Type 1 vs. Type 2 Diabetes Technology Opportunity
2.13. Key Regional Opportunity Hotspots
2.14. High-Growth Opportunity Areas
2.14.1. Insulin-Treated Type 2 Diabetes
2.14.2. Non-Insulin-Treated Type 2 Diabetes
2.14.3. OTC Continuous Glucose Monitoring
2.14.4. Automated Insulin Delivery
2.14.5. Long-Duration CGM
2.14.6. AI-Enabled Diabetes Management

What this section provides: This section gives decision-makers a concise view of market size, historical growth, forecast direction, CGM and insulin-delivery penetration, fastest-growing patient groups, regional demand pockets, and priority commercial opportunities.

3. U.S. Wearable Diabetes Care Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising U.S. Diabetes and Prediabetes Burden
3.1.2. Increasing Continuous Glucose Monitoring Penetration
3.1.3. Expansion of CGM into Type 2 Diabetes
3.1.4. Growing Automated Insulin Delivery Adoption
3.1.5. Expansion of Medicare and Commercial Insurance Coverage
3.1.6. Increasing Pharmacy-Channel Access
3.1.7. Shift Toward Home-Based Diabetes Management
3.1.8. Growing Demand for Real-Time Glucose Data
3.1.9. Rising Smartphone and Connected Device Adoption
3.1.10. Growing Clinical Focus on Time-in-Range Management
3.2. Restraints and Their Impact Analysis
3.2.1. High Out-of-Pocket Device and Consumable Costs
3.2.2. Insurance Coverage and Prior Authorization Complexity
3.2.3. Sensor Adhesion and Skin-Related Issues
3.2.4. Device Discontinuation and Patient Adherence Challenges
3.2.5. Digital Literacy and Technology Access Barriers
3.2.6. Data Privacy and Cybersecurity Concerns
3.2.7. Product Recall and Device Reliability Risk
3.3. Opportunities and Their Impact Analysis
3.3.1. OTC Continuous Glucose Monitoring Expansion
3.3.2. Automated Insulin Delivery for Type 2 Diabetes
3.3.3. Longer-Wear CGM Sensors
3.3.4. Implantable Glucose Monitoring
3.3.5. Simplified Patch Insulin Delivery
3.3.6. Primary Care-Based CGM Adoption
3.3.7. Remote Diabetes Management Programs
3.3.8. Employer and Population Health Programs
3.3.9. AI-Based Glucose Prediction and Decision Support
3.3.10. Multi-Analyte Metabolic Wearables
3.4. Challenges and Their Impact Analysis
3.4.1. Maintaining Long-Term Patient Persistence
3.4.2. Integration Across Sensor and Pump Ecosystems
3.4.3. Clinician Data Overload
3.4.4. Algorithm and Software Validation
3.4.5. Affordability Across Underserved Populations
3.4.6. Rural Diabetes Technology Access
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Device Innovation Cycle Analysis
3.7. Patient Workflow Economics Analysis
3.8. Endocrinology Practice Workflow Economics
3.9. Total Cost of Diabetes Management Analysis
3.10. Patient Lifetime Value and Recurring Consumables Economics
3.11. Prescription-to-Activation Conversion Analysis
3.12. Patient Retention and Device Persistence Analysis

What this section provides: This section explains the clinical, economic, reimbursement, behavioral, and technology forces influencing wearable diabetes device adoption and helps clients quantify market upside, adoption barriers, commercial risks, and emerging growth opportunities.

4. U.S. Wearable Diabetes Care Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis, 2025–2035
4.3.1. CGM Sensor Pricing
4.3.2. Insulin Pump Pricing
4.3.3. Disposable Pod and Infusion Supply Pricing
4.3.4. OTC Glucose Biosensor Pricing
4.3.5. Implantable CGM Pricing
4.4. Value Chain & Supply Chain Analysis
4.4.1. Biosensor and Enzyme Suppliers
4.4.2. Semiconductor and Connectivity Components
4.4.3. Medical-Grade Adhesives and Wearable Materials
4.4.4. Pump Components and Microfluidics
4.4.5. Contract Manufacturing
4.4.6. Device Manufacturers
4.4.7. Pharmacy and DME Distribution
4.4.8. Healthcare Provider Prescribing
4.4.9. Patient Fulfillment and Device Activation
4.5. Impact of Digitalization and Connected Diabetes Care
4.6. Application & Innovation Landscape
4.7. FDA Regulatory Framework Analysis
4.7.1. Integrated Continuous Glucose Monitoring Framework
4.7.2. Automated Insulin Dosing and Pump Regulation
4.7.3. Interoperability Requirements
4.7.4. OTC Glucose Monitoring Regulation
4.7.5. Software as a Medical Device Considerations
4.7.6. Cybersecurity and Post-Market Surveillance
4.8. CMS Reimbursement and Coverage Landscape
4.8.1. Medicare CGM Coverage
4.8.2. Medicare Insulin Pump Coverage
4.8.3. DME Benefit Pathways
4.8.4. Pharmacy Benefit Pathways
4.8.5. Medicaid Access Variation
4.9. Commercial Payer and PBM Coverage Analysis
4.10. Pharmacy vs. DME Access Economics
4.11. Direct-to-Consumer and OTC Channel Analysis
4.12. Import/Export Restrictions & Tariff Impact
4.13. Government Diabetes Prevention and Public Health Programs
4.14. Impact of Escalating Geopolitical and Supply Chain Tensions
4.15. Payer Formulary and Coverage Decision Framework
4.16. Endocrinology and Health-System Technology Adoption Framework

What this section provides: This section delivers a complete view of regulation, reimbursement, payer coverage, pricing, supply chain, pharmacy and DME access, digitalization, technology adoption, and external market forces affecting the U.S. wearable diabetes device ecosystem.

5. U.S. Wearable Diabetes Care Devices Market – By Product Type

5.1. Overview
5.1.1. Segment Share Analysis, By Product Type, 2025 & 2035 (%)
5.1.2. Continuous Glucose Monitoring Systems
5.1.2.1. Real-Time Continuous Glucose Monitoring Systems
5.1.2.2. Intermittently Scanned Continuous Glucose Monitoring Systems
5.1.2.3. Long-Duration Continuous Glucose Monitoring Systems
5.1.2.4. Implantable Continuous Glucose Monitoring Systems
5.1.2.5. OTC Glucose Biosensors
5.1.3. Wearable Insulin Pumps and Automated Insulin Delivery Systems
5.1.3.1. Tubeless Patch Pumps
5.1.3.2. Tubed Wearable Insulin Pumps
5.1.3.3. Hybrid Closed-Loop Systems
5.1.3.4. Automated Insulin Delivery Systems
5.1.3.5. Algorithm-Controlled Insulin Delivery Platforms
5.1.4. Patch-Based Insulin Delivery Devices
5.1.4.1. Disposable Insulin Patch Devices
5.1.4.2. Basal-Bolus Patch Delivery Devices
5.1.4.3. Bolus-Only Patch Delivery Devices
5.1.5. Connected Wearable Insulin-Management Devices and Accessories
5.1.5.1. Connected Insulin Dosing Controllers
5.1.5.2. Wearable Insulin Delivery Accessories
5.1.5.3. Smartphone-Connected Dosing Devices
5.1.6. Emerging Wearable Metabolic and Multi-Analyte Biosensors
5.1.6.1. Glucose-Ketone Monitoring Devices
5.1.6.2. Multi-Analyte Metabolic Sensors
5.1.6.3. Emerging Non-Invasive Glucose Monitoring Technologies

What this section provides: This section identifies the wearable diabetes device categories generating the largest revenue pools and evaluates which products, including CGM, AID, patch delivery and emerging biosensors, are positioned for the strongest growth through 2035.

6. U.S. Wearable Diabetes Care Devices Market – By Diabetes Type

6.1. Overview
6.1.1. Segment Share Analysis, By Diabetes Type, 2025 & 2035 (%)
6.1.2. Type 1 Diabetes
6.1.2.1. Pediatric Type 1 Diabetes
6.1.2.2. Adolescent Type 1 Diabetes
6.1.2.3. Adult Type 1 Diabetes
6.1.3. Insulin-Treated Type 2 Diabetes
6.1.3.1. Multiple Daily Injection Users
6.1.3.2. Pump-Treated Type 2 Diabetes
6.1.3.3. Automated Insulin Delivery Users
6.1.4. Non-Insulin-Treated Type 2 Diabetes
6.1.4.1. Prescription CGM Users
6.1.4.2. OTC CGM Users
6.1.4.3. Medication and Lifestyle Management Users
6.1.5. Prediabetes and Metabolic-Risk Population
6.1.5.1. Prediabetes Monitoring
6.1.5.2. Metabolic Health Monitoring
6.1.5.3. Preventive and Lifestyle-Focused Wearable Use
6.1.6. Gestational and Other Diabetes Populations
6.1.6.1. Gestational Diabetes
6.1.6.2. Secondary and Other Diabetes Types

What this section provides: This section quantifies wearable device demand across the major diabetes populations and helps clients identify where future CGM, insulin-delivery and metabolic-sensing penetration is expected to accelerate most strongly.

7. U.S. Wearable Diabetes Care Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Home and Patient Self-Management
7.1.2.1. Adult Home Users
7.1.2.2. Pediatric Patients and Caregivers
7.1.2.3. Older Adults and Medicare Beneficiaries
7.1.3. Endocrinology and Diabetes Specialty Practices
7.1.3.1. Independent Endocrinology Practices
7.1.3.2. Diabetes Specialty Centers
7.1.3.3. Academic Diabetes Centers
7.1.4. Primary Care Practices
7.1.4.1. Primary Care Physicians
7.1.4.2. Nurse Practitioner-Led Practices
7.1.4.3. Pharmacist-Supported Diabetes Management
7.1.5. Hospitals and Integrated Health Systems
7.1.5.1. Academic Medical Centers
7.1.5.2. Integrated Delivery Networks
7.1.5.3. Hospital Outpatient Diabetes Programs
7.1.5.4. Population Health Programs
7.1.6. Telehealth, Remote Monitoring and Digital Diabetes Care Providers
7.1.6.1. Virtual Diabetes Clinics
7.1.6.2. Remote Patient Monitoring Providers
7.1.6.3. Digital Diabetes Management Platforms
7.1.6.4. Employer-Sponsored Diabetes Programs

What this section provides: This section explains which patient groups, physician settings, health systems and virtual-care models drive wearable diabetes device adoption, prescribing, monitoring activity and recurring device utilization.

8. U.S. Wearable Diabetes Care Devices Market – By Technology & Connectivity

8.1. Overview
8.1.1. Segment Share Analysis, By Technology & Connectivity, 2025 & 2035 (%)
8.1.2. Standalone Continuous Sensing Technologies
8.1.2.1. Dedicated Receiver-Based Systems
8.1.2.2. Smartphone-Display CGM Systems
8.1.2.3. Connected Caregiver-Sharing Systems
8.1.3. CGM-Integrated Automated Insulin Delivery Technologies
8.1.3.1. Sensor-Augmented Pump Systems
8.1.3.2. Predictive Low-Glucose Suspend Systems
8.1.3.3. Hybrid Closed-Loop Systems
8.1.3.4. Advanced Automated Insulin Delivery Systems
8.1.4. Smartphone-First Connected Diabetes Technologies
8.1.4.1. Bluetooth-Enabled Wearables
8.1.4.2. Smartphone-Controlled Insulin Delivery
8.1.4.3. Mobile Glucose Monitoring Applications
8.1.5. Cloud-Connected and AI-Assisted Platforms
8.1.5.1. Cloud-Based Diabetes Data Management
8.1.5.2. AI-Based Glucose Pattern Recognition
8.1.5.3. Predictive Hypoglycemia and Hyperglycemia Analytics
8.1.5.4. Clinical Decision-Support Platforms
8.1.5.5. Remote Care Prioritization Algorithms
8.1.6. Long-Duration and Implantable Sensing Technologies
8.1.6.1. Extended-Wear Transcutaneous Sensors
8.1.6.2. Implantable Glucose Sensors
8.1.6.3. Long-Term Connected Transmitters

What this section provides: This section evaluates the technology architectures shaping diabetes care, including standalone sensing, automated insulin delivery, smartphone control, cloud connectivity, artificial intelligence and long-duration sensing.

9. U.S. Wearable Diabetes Care Devices Market – By Geography

9.1. Introduction
9.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
9.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
9.1.3. Regional Diabetes Population and Disease Burden Analysis
9.1.4. Regional CGM Penetration Analysis
9.1.5. Regional Insulin Pump and AID Adoption Analysis
9.1.6. Regional Medicare, Medicaid and Commercial Coverage Dynamics
9.1.7. Regional Pharmacy and DME Access Analysis
9.1.8. Rural vs. Urban Diabetes Technology Adoption Analysis
9.2. West Region
9.2.1. Regional Overview & Trends
9.2.2. West Region Key Manufacturers, Provider Networks and Access Ecosystem
9.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.2.4. West Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.5. West Region Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.7. West Region Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.2.8. West Region Reimbursement, Pharmacy and DME Access Dynamics
9.2.9. California
9.2.9.1. Overview
9.2.9.2. California Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.9.3. California Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.9.5. California Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.2.9.6. California Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.2.10. Washington
9.2.10.1. Overview
9.2.10.2. Washington Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.10.3. Washington Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.10.5. Washington Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.2.10.6. Washington Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.2.11. Arizona
9.2.11.1. Overview
9.2.11.2. Arizona Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.11.3. Arizona Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.11.5. Arizona Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.2.11.6. Arizona Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.2.12. Colorado
9.2.12.1. Overview
9.2.12.2. Colorado Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.12.3. Colorado Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.12.5. Colorado Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.2.12.6. Colorado Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.2.13. Oregon
9.2.13.1. Overview
9.2.13.2. Oregon Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.13.3. Oregon Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.13.5. Oregon Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.2.13.6. Oregon Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.2.14. Utah
9.2.14.1. Overview
9.2.14.2. Utah Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.14.3. Utah Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.14.5. Utah Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.2.14.6. Utah Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.2.15. Nevada
9.2.15.1. Overview
9.2.15.2. Nevada Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.15.3. Nevada Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.15.5. Nevada Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.2.15.6. Nevada Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.2.16. New Mexico
9.2.16.1. Overview
9.2.16.2. New Mexico Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.16.3. New Mexico Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.16.5. New Mexico Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.2.16.6. New Mexico Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.2.17. Idaho
9.2.17.1. Overview
9.2.17.2. Idaho Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.17.3. Idaho Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.17.5. Idaho Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.2.17.6. Idaho Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.2.18. Montana
9.2.18.1. Overview
9.2.18.2. Montana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.18.3. Montana Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.18.5. Montana Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.2.18.6. Montana Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.2.19. Wyoming
9.2.19.1. Overview
9.2.19.2. Wyoming Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.19.3. Wyoming Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.19.5. Wyoming Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.2.19.6. Wyoming Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.2.20. Alaska
9.2.20.1. Overview
9.2.20.2. Alaska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.20.3. Alaska Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.20.5. Alaska Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.2.20.6. Alaska Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.2.21. Hawaii
9.2.21.1. Overview
9.2.21.2. Hawaii Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.21.3. Hawaii Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.21.5. Hawaii Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.2.21.6. Hawaii Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.3. Northeast Region
9.3.1. Regional Overview & Trends
9.3.2. Northeast Region Key Manufacturers, Provider Networks and Access Ecosystem
9.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.3.4. Northeast Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.5. Northeast Region Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.7. Northeast Region Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.3.8. Northeast Region Reimbursement, Pharmacy and DME Access Dynamics
9.3.9. New York
9.3.9.1. Overview
9.3.9.2. New York Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.9.3. New York Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.9.5. New York Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.3.9.6. New York Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.3.10. Massachusetts
9.3.10.1. Overview
9.3.10.2. Massachusetts Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.10.3. Massachusetts Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.10.5. Massachusetts Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.3.10.6. Massachusetts Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.3.11. New Jersey
9.3.11.1. Overview
9.3.11.2. New Jersey Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.11.3. New Jersey Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.11.5. New Jersey Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.3.11.6. New Jersey Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.3.12. Pennsylvania
9.3.12.1. Overview
9.3.12.2. Pennsylvania Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.12.3. Pennsylvania Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.12.5. Pennsylvania Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.3.12.6. Pennsylvania Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.3.13. Connecticut
9.3.13.1. Overview
9.3.13.2. Connecticut Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.13.3. Connecticut Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.13.5. Connecticut Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.3.13.6. Connecticut Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.3.14. Maine
9.3.14.1. Overview
9.3.14.2. Maine Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.14.3. Maine Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.14.5. Maine Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.3.14.6. Maine Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.3.15. Vermont
9.3.15.1. Overview
9.3.15.2. Vermont Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.15.3. Vermont Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.15.5. Vermont Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.3.15.6. Vermont Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.3.16. New Hampshire
9.3.16.1. Overview
9.3.16.2. New Hampshire Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.16.3. New Hampshire Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.16.5. New Hampshire Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.3.16.6. New Hampshire Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.3.17. Rhode Island
9.3.17.1. Overview
9.3.17.2. Rhode Island Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.17.3. Rhode Island Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.17.5. Rhode Island Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.3.17.6. Rhode Island Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.3.18. Delaware
9.3.18.1. Overview
9.3.18.2. Delaware Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.18.3. Delaware Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.18.5. Delaware Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.3.18.6. Delaware Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.4. South Region
9.4.1. Regional Overview & Trends
9.4.2. South Region Key Manufacturers, Provider Networks and Access Ecosystem
9.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.4.4. South Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.5. South Region Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.7. South Region Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.4.8. South Region Reimbursement, Pharmacy and DME Access Dynamics
9.4.9. Texas
9.4.9.1. Overview
9.4.9.2. Texas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.9.3. Texas Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.9.5. Texas Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.4.9.6. Texas Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.4.10. Florida
9.4.10.1. Overview
9.4.10.2. Florida Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.10.3. Florida Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.10.5. Florida Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.4.10.6. Florida Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.4.11. Georgia
9.4.11.1. Overview
9.4.11.2. Georgia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.11.3. Georgia Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.11.5. Georgia Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.4.11.6. Georgia Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.4.12. North Carolina
9.4.12.1. Overview
9.4.12.2. North Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.12.3. North Carolina Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.12.5. North Carolina Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.4.12.6. North Carolina Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.4.13. Tennessee
9.4.13.1. Overview
9.4.13.2. Tennessee Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.13.3. Tennessee Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.13.5. Tennessee Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.4.13.6. Tennessee Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.4.14. South Carolina
9.4.14.1. Overview
9.4.14.2. South Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.14.3. South Carolina Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.14.5. South Carolina Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.4.14.6. South Carolina Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.4.15. Alabama
9.4.15.1. Overview
9.4.15.2. Alabama Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.15.3. Alabama Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.15.5. Alabama Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.4.15.6. Alabama Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.4.16. Mississippi
9.4.16.1. Overview
9.4.16.2. Mississippi Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.16.3. Mississippi Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.16.5. Mississippi Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.4.16.6. Mississippi Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.4.17. Louisiana
9.4.17.1. Overview
9.4.17.2. Louisiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.17.3. Louisiana Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.17.5. Louisiana Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.4.17.6. Louisiana Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.4.18. Arkansas
9.4.18.1. Overview
9.4.18.2. Arkansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.18.3. Arkansas Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.18.5. Arkansas Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.4.18.6. Arkansas Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.4.19. Kentucky
9.4.19.1. Overview
9.4.19.2. Kentucky Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.19.3. Kentucky Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.19.5. Kentucky Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.4.19.6. Kentucky Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.4.20. Oklahoma
9.4.20.1. Overview
9.4.20.2. Oklahoma Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.20.3. Oklahoma Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.20.5. Oklahoma Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.4.20.6. Oklahoma Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.4.21. Virginia
9.4.21.1. Overview
9.4.21.2. Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.21.3. Virginia Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.21.5. Virginia Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.4.21.6. Virginia Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.4.22. Maryland
9.4.22.1. Overview
9.4.22.2. Maryland Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.22.3. Maryland Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.22.5. Maryland Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.4.22.6. Maryland Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.4.23. West Virginia
9.4.23.1. Overview
9.4.23.2. West Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.23.3. West Virginia Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.23.5. West Virginia Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.4.23.6. West Virginia Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.5. Midwest Region
9.5.1. Regional Overview & Trends
9.5.2. Midwest Region Key Manufacturers, Provider Networks and Access Ecosystem
9.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.5.4. Midwest Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.5. Midwest Region Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.7. Midwest Region Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.5.8. Midwest Region Reimbursement, Pharmacy and DME Access Dynamics
9.5.9. Illinois
9.5.9.1. Overview
9.5.9.2. Illinois Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.9.3. Illinois Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.9.5. Illinois Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.5.9.6. Illinois Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.5.10. Ohio
9.5.10.1. Overview
9.5.10.2. Ohio Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.10.3. Ohio Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.10.5. Ohio Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.5.10.6. Ohio Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.5.11. Michigan
9.5.11.1. Overview
9.5.11.2. Michigan Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.11.3. Michigan Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.11.5. Michigan Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.5.11.6. Michigan Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.5.12. Minnesota
9.5.12.1. Overview
9.5.12.2. Minnesota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.12.3. Minnesota Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.12.5. Minnesota Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.5.12.6. Minnesota Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.5.13. Indiana
9.5.13.1. Overview
9.5.13.2. Indiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.13.3. Indiana Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.13.5. Indiana Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.5.13.6. Indiana Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.5.14. Wisconsin
9.5.14.1. Overview
9.5.14.2. Wisconsin Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.14.3. Wisconsin Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.14.5. Wisconsin Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.5.14.6. Wisconsin Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.5.15. Missouri
9.5.15.1. Overview
9.5.15.2. Missouri Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.15.3. Missouri Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.15.5. Missouri Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.5.15.6. Missouri Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.5.16. Iowa
9.5.16.1. Overview
9.5.16.2. Iowa Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.16.3. Iowa Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.16.5. Iowa Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.5.16.6. Iowa Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.5.17. Kansas
9.5.17.1. Overview
9.5.17.2. Kansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.17.3. Kansas Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.17.5. Kansas Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.5.17.6. Kansas Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.5.18. Nebraska
9.5.18.1. Overview
9.5.18.2. Nebraska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.18.3. Nebraska Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.18.5. Nebraska Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.5.18.6. Nebraska Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.5.19. North Dakota
9.5.19.1. Overview
9.5.19.2. North Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.19.3. North Dakota Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.19.5. North Dakota Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.5.19.6. North Dakota Reimbursement, Pharmacy and Diabetes Technology Access Analysis
9.5.20. South Dakota
9.5.20.1. Overview
9.5.20.2. South Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.20.3. South Dakota Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
9.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.20.5. South Dakota Market Size and Forecast, By Technology & Connectivity, 2021–2035 (US$ Billion)
9.5.20.6. South Dakota Reimbursement, Pharmacy and Diabetes Technology Access Analysis

What this section provides: This section delivers detailed regional and state-level market intelligence across all 50 U.S. states, helping clients identify wearable diabetes device adoption hotspots, diabetes-burden markets, CGM and AID opportunities, reimbursement differences, pharmacy and DME access dynamics, and state-level commercial priorities.

10. U.S. Wearable Diabetes Care Devices Market: Competitive Landscape & Company Profiles

10.1. Market Share Analysis, 2025
10.1.1. Overall Wearable Diabetes Device Market Share
10.1.2. Continuous Glucose Monitoring Market Share
10.1.3. Wearable Insulin Pump Market Share
10.1.4. Automated Insulin Delivery Market Share
10.1.5. Emerging Diabetes Wearable Market Positioning
10.2. Company Positioning Matrix
10.2.1. Leaders
10.2.2. Challengers
10.2.3. Innovators
10.2.4. Emerging Players
10.3. Company Profiles
10.3.1. Abbott Laboratories
10.3.2. Dexcom, Inc.
10.3.3. Medtronic plc
10.3.4. Insulet Corporation
10.3.5. Tandem Diabetes Care, Inc.
10.3.6. Senseonics Holdings, Inc.
10.3.7. Beta Bionics, Inc.
10.3.8. Sequel Med Tech, LLC
10.3.9. embecta Corp.
10.3.10. CeQur Corporation
10.3.11. Modular Medical, Inc.
10.3.12. Ascensia Diabetes Care Holdings AG
10.3.13. Roche Diabetes Care
10.3.14. LifeScan, Inc.
10.3.15. AgaMatrix, Inc.
10.3.16. DarioHealth Corp.
10.3.17. Glooko, Inc.
10.3.18. Teladoc Health, Inc. / Livongo
10.3.19. Ypsomed Holding AG
10.3.20. Tidepool
10.3.21. EOFlow Co., Ltd.
10.3.22. i-SENS, Inc.
10.3.23. Sinocare Inc.

Note: Each company profile will include company overview, U.S. wearable diabetes device portfolio, CGM or insulin-delivery positioning, FDA and regulatory status, U.S. reimbursement and market-access strategy, technology partnerships, interoperability strategy, financial positioning, product pipeline, clinical evidence, recent developments, and competitive outlook.

10.4. Competitive Benchmarking by Product Portfolio
10.5. CGM Competitive Benchmarking
10.6. Insulin Pump and AID Competitive Benchmarking
10.7. Sensor Wear-Duration Benchmarking
10.8. Interoperability and Ecosystem Partnership Analysis
10.9. Pharmacy and Reimbursement Access Benchmarking
10.10. Mergers, Acquisitions and Strategic Partnerships
10.11. Product Launch and FDA Approval Benchmarking

What this section provides: This section gives clients company-level competitive intelligence, market-share visibility, product benchmarking, ecosystem positioning, reimbursement strategy, innovation direction, regulatory progress, partnership activity, and strategic insights on major wearable diabetes technology participants.

11. U.S. Wearable Diabetes Care Devices Market: Future Market Outlook, 2026–2035

11.1. Scenario Analysis
11.1.1. Optimistic Scenario
11.1.2. Realistic Scenario
11.1.3. Pessimistic Scenario
11.2. Disruptive Technologies Impact
11.2.1. OTC Continuous Glucose Monitoring
11.2.2. Automated Insulin Delivery Expansion into Type 2 Diabetes
11.2.3. Long-Duration and Implantable CGM
11.2.4. Multi-Analyte Glucose and Ketone Sensing
11.2.5. AI-Assisted Diabetes Decision Support
11.2.6. Fully Automated Closed-Loop Insulin Delivery
11.2.7. Smartphone-Controlled Wearable Insulin Delivery
11.2.8. Predictive Glucose Analytics
11.2.9. Non-Invasive Glucose Monitoring
11.2.10. Next-Generation Miniaturized Biosensors
11.3. Emerging Business Trends
11.3.1. Transition from Device Sales to Connected Ecosystems
11.3.2. Recurring Sensor and Consumables Revenue Models
11.3.3. Pharmacy Benefit Expansion
11.3.4. Consumerization of Glucose Monitoring
11.3.5. Value-Based Diabetes Technology Contracting
11.3.6. Virtual Diabetes Management Integration
11.4. Business Opportunities for Startups and Existing Players
11.5. Investment Prioritization Matrix
11.6. Patient Population Expansion Opportunity Matrix
11.7. Technology Commercialization Risk Matrix
11.8. Market Entry Opportunity by Product Category
11.9. Market Entry Opportunity by U.S. Region

What this section provides: This section prepares clients for technology disruption, addressable-population expansion, changing business models, emerging investment opportunities, competitive shifts, and realistic market adoption scenarios through 2035.

12. U.S. Wearable Diabetes Care Devices Market: Strategic Recommendations

12.1. Recommendations for Wearable Diabetes Device Manufacturers
12.1.1. Product Innovation Priorities
12.1.2. Sensor Wear-Time and Patient Experience Strategy
12.1.3. AID and Interoperability Strategy
12.1.4. Type 2 Diabetes Expansion Strategy
12.1.5. OTC Market Strategy
12.2. Recommendations for Healthcare Providers and Health Systems
12.2.1. CGM Adoption Workflow
12.2.2. Patient Selection and Onboarding
12.2.3. Diabetes Data Management
12.2.4. Remote Monitoring Integration
12.3. Recommendations for Payers and Pharmacy Benefit Managers
12.3.1. Coverage Expansion Strategy
12.3.2. Formulary Design Considerations
12.3.3. Outcomes-Based Contracting
12.3.4. Total Cost of Care Evaluation
12.4. Recommendations for Investors and Private Equity Firms
12.5. Recommendations for Retail Pharmacies, DME Suppliers and Channel Partners
12.6. Recommendations for Digital Diabetes Care Providers
12.7. Recommendations for New Entrants and Startups
12.8. Go-to-Market Strategy Considerations
12.9. Product Positioning and Portfolio Expansion Guidance
12.10. U.S. State Prioritization Strategy
12.11. Reimbursement and Market Access Strategy
12.12. Strategic Partnership and Interoperability Strategy

What this section provides: This section converts market intelligence into actionable recommendations for product development, reimbursement, patient access, commercial expansion, technology partnerships, state prioritization, investment planning, portfolio strategy, and competitive differentiation.

13. U.S. Wearable Diabetes Care Devices Market: Disclaimer

13.1. Scope Limitation
13.2. Data Use Limitation
13.3. Market Estimation Limitation
13.4. Forecasting Limitation
13.5. Patient Population Modeling Limitation
13.6. Regulatory and Reimbursement Limitation
13.7. Legal Disclaimer
13.8. Third-Party Data Disclaimer
13.9. Company and Product Information Disclaimer

What this section provides: This section clarifies the report’s scope, data-use conditions, market-model limitations, forecasting assumptions, regulatory and reimbursement considerations, third-party information boundaries, and legal limitations.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Wearable Diabetes Care Devices Market: Market Definition and Scope
TABLE 3: U.S. Wearable Diabetes Care Devices Market: Research Methodology Framework
TABLE 4: U.S. Wearable Diabetes Care Devices Market: Market Sizing, Patient Penetration and Recurring Revenue Model
TABLE 5: U.S. Wearable Diabetes Care Devices Market: Key Assumptions
TABLE 6: U.S. Wearable Diabetes Care Devices Market: Market Ecosystem Overview
TABLE 7: U.S. Wearable Diabetes Care Devices Market: Stakeholder Analysis
TABLE 8: U.S. Wearable Diabetes Care Devices Market: Executive Summary Snapshot, 2025
TABLE 9: U.S. Wearable Diabetes Care Devices Market: Analyst Viewpoint Summary
TABLE 10: U.S. Wearable Diabetes Care Devices Market: Market Attractiveness Index
TABLE 11: U.S. Wearable Diabetes Care Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 12: U.S. Wearable Diabetes Care Devices Market: Base Year Market Positioning, 2025
TABLE 13: U.S. Wearable Diabetes Care Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 14: U.S. Wearable Diabetes Care Devices Market: High-Growth Opportunity Areas, 2026–2035
TABLE 15: U.S. Wearable Diabetes Care Devices Market: Drivers; Impact Analysis
TABLE 16: U.S. Wearable Diabetes Care Devices Market: Restraints; Impact Analysis
TABLE 17: U.S. Wearable Diabetes Care Devices Market: Opportunities; Impact Analysis
TABLE 18: U.S. Wearable Diabetes Care Devices Market: Challenges; Impact Analysis
TABLE 19: U.S. Wearable Diabetes Care Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 20: U.S. Wearable Diabetes Care Devices Market: Device Innovation Cycle Analysis
TABLE 21: U.S. Wearable Diabetes Care Devices Market: Patient Workflow Economics Matrix
TABLE 22: U.S. Wearable Diabetes Care Devices Market: Endocrinology Practice Workflow Economics Matrix
TABLE 23: U.S. Wearable Diabetes Care Devices Market: Total Cost of Diabetes Management Analysis
TABLE 24: U.S. Wearable Diabetes Care Devices Market: Patient Lifetime Value and Recurring Consumables Economics
TABLE 25: U.S. Wearable Diabetes Care Devices Market: Prescription-to-Activation and Patient Persistence Analysis
TABLE 26: U.S. Wearable Diabetes Care Devices Market: PESTEL Analysis
TABLE 27: U.S. Wearable Diabetes Care Devices Market: Porter’s Five Forces Analysis
TABLE 28: U.S. Wearable Diabetes Care Devices Market: Pricing Trend Analysis, 2025–2035
TABLE 29: U.S. Wearable Diabetes Care Devices Market: Value Chain Analysis
TABLE 30: U.S. Wearable Diabetes Care Devices Market: Supply Chain Analysis
TABLE 31: U.S. Wearable Diabetes Care Devices Market: Digitalization and Connected Diabetes Care Impact
TABLE 32: U.S. Wearable Diabetes Care Devices Market: Application & Innovation Landscape
TABLE 33: U.S. Wearable Diabetes Care Devices Market: FDA Regulatory Framework Analysis
TABLE 34: U.S. Wearable Diabetes Care Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 35: U.S. Wearable Diabetes Care Devices Market: Commercial Payer and PBM Coverage Analysis
TABLE 36: U.S. Wearable Diabetes Care Devices Market: Pharmacy vs. DME Access Economics
TABLE 37: U.S. Wearable Diabetes Care Devices Market: Direct-to-Consumer and OTC Channel Analysis
TABLE 38: U.S. Wearable Diabetes Care Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 39: U.S. Wearable Diabetes Care Devices Market: Government Diabetes Programs and Public Health Initiatives
TABLE 40: U.S. Wearable Diabetes Care Devices Market: Geopolitical and Supply Chain Risk Analysis
TABLE 41: U.S. Wearable Diabetes Care Devices Market: Payer Formulary and Coverage Decision Framework
TABLE 42: U.S. Wearable Diabetes Care Devices Market: Provider Technology Adoption Framework
TABLE 43: U.S. Wearable Diabetes Care Devices Market: Product Type Snapshot, 2025
TABLE 44: Segment Dashboard; Definition and Scope, by Product Type
TABLE 45: U.S. Wearable Diabetes Care Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 46: U.S. Wearable Diabetes Care Devices Market: Segment Share Analysis, by Product Type, 2025 & 2035 (%)
TABLE 47: U.S. Wearable Diabetes Care Devices Market: Continuous Glucose Monitoring Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: U.S. Wearable Diabetes Care Devices Market: Wearable Insulin Pumps and Automated Insulin Delivery Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: U.S. Wearable Diabetes Care Devices Market: Patch-Based Insulin Delivery Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 50: U.S. Wearable Diabetes Care Devices Market: Connected Wearable Insulin-Management Devices and Accessories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: U.S. Wearable Diabetes Care Devices Market: Emerging Wearable Metabolic and Multi-Analyte Biosensors Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: U.S. Wearable Diabetes Care Devices Market: Diabetes Type Snapshot, 2025
TABLE 53: Segment Dashboard; Definition and Scope, by Diabetes Type
TABLE 54: U.S. Wearable Diabetes Care Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 55: U.S. Wearable Diabetes Care Devices Market: Segment Share Analysis, by Diabetes Type, 2025 & 2035 (%)
TABLE 56: U.S. Wearable Diabetes Care Devices Market: Type 1 Diabetes Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. Wearable Diabetes Care Devices Market: Insulin-Treated Type 2 Diabetes Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. Wearable Diabetes Care Devices Market: Non-Insulin-Treated Type 2 Diabetes Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 59: U.S. Wearable Diabetes Care Devices Market: Prediabetes and Metabolic-Risk Population Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: U.S. Wearable Diabetes Care Devices Market: Gestational and Other Diabetes Populations Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: U.S. Wearable Diabetes Care Devices Market: End User Snapshot, 2025
TABLE 62: Segment Dashboard; Definition and Scope, by End User
TABLE 63: U.S. Wearable Diabetes Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 64: U.S. Wearable Diabetes Care Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 65: U.S. Wearable Diabetes Care Devices Market: Home and Patient Self-Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. Wearable Diabetes Care Devices Market: Endocrinology and Diabetes Specialty Practices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: U.S. Wearable Diabetes Care Devices Market: Primary Care Practices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 68: U.S. Wearable Diabetes Care Devices Market: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: U.S. Wearable Diabetes Care Devices Market: Telehealth, Remote Monitoring and Digital Diabetes Care Providers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: U.S. Wearable Diabetes Care Devices Market: Technology & Connectivity Snapshot, 2025
TABLE 71: Segment Dashboard; Definition and Scope, by Technology & Connectivity
TABLE 72: U.S. Wearable Diabetes Care Devices Market, by Technology & Connectivity, 2021–2035 (US$ Billion)
TABLE 73: U.S. Wearable Diabetes Care Devices Market: Segment Share Analysis, by Technology & Connectivity, 2025 & 2035 (%)
TABLE 74: U.S. Wearable Diabetes Care Devices Market: Standalone Continuous Sensing Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. Wearable Diabetes Care Devices Market: CGM-Integrated Automated Insulin Delivery Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: U.S. Wearable Diabetes Care Devices Market: Smartphone-First Connected Diabetes Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 77: U.S. Wearable Diabetes Care Devices Market: Cloud-Connected and AI-Assisted Platforms Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 78: U.S. Wearable Diabetes Care Devices Market: Long-Duration and Implantable Sensing Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 79: U.S. Wearable Diabetes Care Devices Market: Regional Snapshot, 2025
TABLE 80: Segment Dashboard; Definition and Scope, by Geography
TABLE 81: U.S. Wearable Diabetes Care Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 82: U.S. Wearable Diabetes Care Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 83: West Region U.S. Wearable Diabetes Care Devices Market: Regional Overview and Trends
TABLE 84: West Region U.S. Wearable Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 85: West Region U.S. Wearable Diabetes Care Devices Market: Reimbursement, Pharmacy and DME Access Dynamics
TABLE 86: Northeast Region U.S. Wearable Diabetes Care Devices Market: Regional Overview and Trends
TABLE 87: Northeast Region U.S. Wearable Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 88: Northeast Region U.S. Wearable Diabetes Care Devices Market: Reimbursement, Pharmacy and DME Access Dynamics
TABLE 89: South Region U.S. Wearable Diabetes Care Devices Market: Regional Overview and Trends
TABLE 90: South Region U.S. Wearable Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 91: South Region U.S. Wearable Diabetes Care Devices Market: Reimbursement, Pharmacy and DME Access Dynamics
TABLE 92: Midwest Region U.S. Wearable Diabetes Care Devices Market: Regional Overview and Trends
TABLE 93: Midwest Region U.S. Wearable Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 94: Midwest Region U.S. Wearable Diabetes Care Devices Market: Reimbursement, Pharmacy and DME Access Dynamics
TABLE 95: California Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 96: Washington Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 97: Arizona Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 98: Colorado Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 99: Oregon Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 100: Utah Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 101: Nevada Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 102: New Mexico Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 103: Idaho Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 104: Montana Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 105: Wyoming Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 106: Alaska Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 107: Hawaii Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 108: New York Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 109: Massachusetts Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 110: New Jersey Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 111: Pennsylvania Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 112: Connecticut Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 113: Maine Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 114: Vermont Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 115: New Hampshire Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 116: Rhode Island Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 117: Delaware Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 118: Texas Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 119: Florida Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 120: Georgia Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 121: North Carolina Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 122: Tennessee Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 123: South Carolina Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 124: Alabama Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 125: Mississippi Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 126: Louisiana Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 127: Arkansas Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 128: Kentucky Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 129: Oklahoma Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 130: Virginia Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 131: Maryland Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 132: West Virginia Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 133: Illinois Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 134: Ohio Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 135: Michigan Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 136: Minnesota Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 137: Indiana Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 138: Wisconsin Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 139: Missouri Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 140: Iowa Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 141: Kansas Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 142: Nebraska Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 143: North Dakota Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 144: South Dakota Wearable Diabetes Care Devices Market: Market Size and Segment Forecast, 2021–2035 (US$ Billion)
TABLE 145: U.S. Wearable Diabetes Care Devices Market: Competitive Landscape Snapshot, 2025
TABLE 146: U.S. Wearable Diabetes Care Devices Market: Key Company Market Share Analysis, 2025
TABLE 147: U.S. Wearable Diabetes Care Devices Market: Company Positioning Matrix
TABLE 148: U.S. Wearable Diabetes Care Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 149: U.S. Wearable Diabetes Care Devices Market: CGM Competitive Benchmarking
TABLE 150: U.S. Wearable Diabetes Care Devices Market: Insulin Pump and AID Competitive Benchmarking
TABLE 151: U.S. Wearable Diabetes Care Devices Market: Sensor Wear-Duration Benchmarking
TABLE 152: U.S. Wearable Diabetes Care Devices Market: Interoperability and Ecosystem Partnership Analysis
TABLE 153: U.S. Wearable Diabetes Care Devices Market: Pharmacy and Reimbursement Access Benchmarking
TABLE 154: U.S. Wearable Diabetes Care Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 155: Abbott Laboratories: Company Profile
TABLE 156: Dexcom, Inc.: Company Profile
TABLE 157: Medtronic plc: Company Profile
TABLE 158: Insulet Corporation: Company Profile
TABLE 159: Tandem Diabetes Care, Inc.: Company Profile
TABLE 160: Senseonics Holdings, Inc.: Company Profile
TABLE 161: Beta Bionics, Inc.: Company Profile
TABLE 162: Sequel Med Tech, LLC: Company Profile
TABLE 163: embecta Corp.: Company Profile
TABLE 164: CeQur Corporation: Company Profile
TABLE 165: Modular Medical, Inc.: Company Profile
TABLE 166: Ascensia Diabetes Care Holdings AG: Company Profile
TABLE 167: Roche Diabetes Care: Company Profile
TABLE 168: LifeScan, Inc.: Company Profile
TABLE 169: AgaMatrix, Inc.: Company Profile
TABLE 170: DarioHealth Corp.: Company Profile
TABLE 171: Glooko, Inc.: Company Profile
TABLE 172: Teladoc Health, Inc. / Livongo: Company Profile
TABLE 173: Ypsomed Holding AG: Company Profile
TABLE 174: Tidepool: Company Profile
TABLE 175: EOFlow Co., Ltd.: Company Profile
TABLE 176: i-SENS, Inc.: Company Profile
TABLE 177: Sinocare Inc.: Company Profile
TABLE 178: U.S. Wearable Diabetes Care Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 179: U.S. Wearable Diabetes Care Devices Market: Disruptive Technologies Impact Matrix
TABLE 180: U.S. Wearable Diabetes Care Devices Market: Emerging Business Trends
TABLE 181: U.S. Wearable Diabetes Care Devices Market: Business Opportunities for Startups and Existing Players
TABLE 182: U.S. Wearable Diabetes Care Devices Market: Investment Prioritization Matrix
TABLE 183: U.S. Wearable Diabetes Care Devices Market: Patient Population Expansion Opportunity Matrix
TABLE 184: U.S. Wearable Diabetes Care Devices Market: Technology Commercialization Risk Matrix
TABLE 185: U.S. Wearable Diabetes Care Devices Market: Market Entry Opportunity by Product Type
TABLE 186: U.S. Wearable Diabetes Care Devices Market: Market Entry Opportunity by U.S. Region
TABLE 187: U.S. Wearable Diabetes Care Devices Market: Strategic Recommendations for Device Manufacturers
TABLE 188: U.S. Wearable Diabetes Care Devices Market: Strategic Recommendations for Healthcare Providers and Health Systems
TABLE 189: U.S. Wearable Diabetes Care Devices Market: Strategic Recommendations for Payers and PBMs
TABLE 190: U.S. Wearable Diabetes Care Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 191: U.S. Wearable Diabetes Care Devices Market: Strategic Recommendations for Pharmacies, DME Suppliers and Channel Partners
TABLE 192: U.S. Wearable Diabetes Care Devices Market: Strategic Recommendations for Digital Diabetes Care Providers
TABLE 193: U.S. Wearable Diabetes Care Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 194: U.S. Wearable Diabetes Care Devices Market: Go-to-Market Strategy Considerations
TABLE 195: U.S. Wearable Diabetes Care Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 196: U.S. Wearable Diabetes Care Devices Market: U.S. State Prioritization Strategy
TABLE 197: U.S. Wearable Diabetes Care Devices Market: Reimbursement and Market Access Strategy
TABLE 198: U.S. Wearable Diabetes Care Devices Market: Strategic Partnership and Interoperability Strategy
TABLE 199: U.S. Wearable Diabetes Care Devices Market: Scope Limitation
TABLE 200: U.S. Wearable Diabetes Care Devices Market: Data Use Limitation
TABLE 201: U.S. Wearable Diabetes Care Devices Market: Market Estimation and Forecasting Limitation
TABLE 202: U.S. Wearable Diabetes Care Devices Market: Regulatory and Reimbursement Limitation
TABLE 203: U.S. Wearable Diabetes Care Devices Market: Legal and Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Wearable Diabetes Care Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Market Sizing and Forecasting Framework
FIGURE 4: Market Ecosystem
FIGURE 5: Value Chain Analysis
FIGURE 6: Supply Chain Analysis
FIGURE 7: PESTEL Analysis
FIGURE 8: Porter’s Five Forces Analysis
FIGURE 9: Market Attractiveness Analysis
FIGURE 10: Market Dynamics
FIGURE 11: Innovation & Patent Landscape, 2021–2025
FIGURE 12: Patient Workflow Economics Framework
FIGURE 13: Endocrinology Practice Workflow Economics Framework
FIGURE 14: Patient Activation and Persistence Funnel
FIGURE 15: U.S. Wearable Diabetes Care Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 16: U.S. Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 17: U.S. Wearable Diabetes Care Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 18: Product Type Segment Market Share Analysis, 2025 & 2035
FIGURE 19: Product Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 20: Continuous Glucose Monitoring Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 21: Wearable Insulin Pumps and Automated Insulin Delivery Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Patch-Based Insulin Delivery Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Connected Wearable Insulin-Management Devices and Accessories Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Emerging Wearable Metabolic and Multi-Analyte Biosensors Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: Diabetes Type Segment Market Share Analysis, 2025 & 2035
FIGURE 26: Diabetes Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Type 1 Diabetes Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Insulin-Treated Type 2 Diabetes Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Non-Insulin-Treated Type 2 Diabetes Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Prediabetes and Metabolic-Risk Population Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Gestational and Other Diabetes Populations Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 33: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Home and Patient Self-Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Endocrinology and Diabetes Specialty Practices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Primary Care Practices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Hospitals and Integrated Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Telehealth, Remote Monitoring and Digital Diabetes Care Providers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Technology & Connectivity Segment Market Share Analysis, 2025 & 2035
FIGURE 40: Technology & Connectivity Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Standalone Continuous Sensing Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: CGM-Integrated Automated Insulin Delivery Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Smartphone-First Connected Diabetes Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Cloud-Connected and AI-Assisted Platforms Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Long-Duration and Implantable Sensing Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 47: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: West Region U.S. Wearable Diabetes Care Devices Market Share Analysis, 2025
FIGURE 49: West Region Market Share Analysis by State, 2025
FIGURE 50: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Northeast Region U.S. Wearable Diabetes Care Devices Market Share Analysis, 2025
FIGURE 52: Northeast Region Market Share Analysis by State, 2025
FIGURE 53: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: South Region U.S. Wearable Diabetes Care Devices Market Share Analysis, 2025
FIGURE 55: South Region Market Share Analysis by State, 2025
FIGURE 56: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: Midwest Region U.S. Wearable Diabetes Care Devices Market Share Analysis, 2025
FIGURE 58: Midwest Region Market Share Analysis by State, 2025
FIGURE 59: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: California Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Washington Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Arizona Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Colorado Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Oregon Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Utah Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Nevada Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: New Mexico Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Idaho Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Montana Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Wyoming Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Alaska Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Hawaii Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: New York Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Massachusetts Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: New Jersey Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: Pennsylvania Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Connecticut Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: Maine Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Vermont Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: New Hampshire Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Rhode Island Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Delaware Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: Texas Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: Florida Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Georgia Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: North Carolina Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Tennessee Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: South Carolina Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: Alabama Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Mississippi Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Louisiana Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Arkansas Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Kentucky Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: Oklahoma Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Virginia Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Maryland Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: West Virginia Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Illinois Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Ohio Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Michigan Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Minnesota Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Indiana Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Wisconsin Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Missouri Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Iowa Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Kansas Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Nebraska Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: North Dakota Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: South Dakota Wearable Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 111: Company Positioning Matrix
FIGURE 112: Key Player Product Portfolio Benchmarking
FIGURE 113: CGM Competitive Benchmarking
FIGURE 114: Insulin Pump and Automated Insulin Delivery Competitive Benchmarking
FIGURE 115: Sensor Wear-Duration Benchmarking
FIGURE 116: Interoperability and Ecosystem Partnership Map
FIGURE 117: Pharmacy and Reimbursement Access Benchmarking
FIGURE 118: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 119: Wearable Diabetes Device Innovation Roadmap
FIGURE 120: OTC Continuous Glucose Monitoring Adoption Roadmap
FIGURE 121: Automated Insulin Delivery Expansion Opportunity Map
FIGURE 122: Long-Duration and Implantable CGM Technology Roadmap
FIGURE 123: AI-Assisted Diabetes Management Opportunity Map
FIGURE 124: Future Market Scenario Analysis, 2026–2035
FIGURE 125: Disruptive Technologies Impact Matrix
FIGURE 126: Emerging Business Trends Matrix
FIGURE 127: Patient Population Expansion Opportunity Matrix
FIGURE 128: Investment Prioritization Matrix
FIGURE 129: Technology Commercialization Risk Matrix
FIGURE 130: Strategic Growth Roadmap for U.S. Wearable Diabetes Device Companies
FIGURE 131: Go-to-Market Strategy Framework
FIGURE 132: Product Positioning and Portfolio Expansion Framework
FIGURE 133: U.S. State Prioritization Framework
FIGURE 134: Reimbursement and Market Access Strategy Framework
FIGURE 135: Strategic Partnership and Interoperability Framework
FIGURE 136: Report Scope and Disclaimer Framework